Welcome to our dedicated page for Amrize SEC filings (Ticker: AMRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amrize Ltd (NYSE: AMRZ) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents. As a Switzerland-incorporated issuer listed on the New York Stock Exchange and the SIX Swiss Exchange, Amrize files reports with the U.S. Securities and Exchange Commission that give investors structured information about its operations and financial condition.
Recent Form 8-K filings from Amrize have reported quarterly financial results and related investor materials. These filings typically reference earnings press releases and investor presentations that discuss revenue by segment, non-GAAP metrics such as Adjusted EBITDA, Free Cash Flow, Net Debt and Net Leverage Ratio, and commentary on the performance of the Building Materials and Building Envelope segments. They also confirm details such as the company’s jurisdiction of incorporation in Switzerland and its principal executive office location in Zug.
On this page, investors can monitor new 8-K filings as they are released, along with other SEC forms when available, such as annual and quarterly reports that provide more comprehensive detail on Amrize’s business, risk factors and segment information. Filings related to capital structure, such as debt issuance, and any documents reporting significant events or transactions, are also part of the regulatory record.
Stock Titan enhances these filings with AI-powered summaries designed to explain the main points of lengthy documents in clear language. This can help readers quickly understand key topics such as segment performance, changes in leverage, major investments, or strategic initiatives like the ASPIRE program, while still allowing direct access to the full original filings for detailed analysis.
Amrize Ltd (AMRZ) director share purchase disclosed. A reporting person serving as a director of Amrize Ltd bought 2,000 ordinary shares on 11/19/2025 at a price of $47.34 per share in an open-market purchase coded "P." After this transaction, the director beneficially owns 4,958 ordinary shares held directly. The filing does not report any transactions in derivative securities.
Amrize Ltd (AMRZ) reported an insider purchase. An officer, President, Building Materials, acquired 4,000 ordinary shares on 11/04/2025 at $50.685 per share.
Following the transaction, the insider beneficially owned 18,101 shares, held directly. The filing was made by one reporting person on a Form 4.
Amrize Ltd (AMRZ) disclosed a Form 4 showing its Chief Technology Officer purchased a total of 4,000 ordinary shares on 10/31/2025 across two open‑market trades at $51.78 (3,000 shares) and $51.76 (1,000 shares). Following these transactions, the officer directly holds 9,000 shares.
The filing notes the trades were executed in Swiss Francs at CHF 41.51 and CHF 41.50 per share, converted using the transaction‑date exchange rate of USD 1.00 = CHF 0.8017.
Amrize Ltd (AMRZ) insider activity: On 10/30/2025, the company’s Chairman & CEO, who is also a Director, reported two open‑market purchases (Transaction Code P): 55,000 ordinary shares at a weighted average price of $52.64 (converted from CHF 42.05) and 55,000 ordinary shares at a weighted average price of $52.88. The purchases were executed in multiple trades within the stated price ranges.
Following these transactions, beneficial ownership was 1,505,000 shares held directly and 505,000 shares held indirectly by spouse.
Amrize Ltd and its subsidiary Amrize Finance US LLC filed a Form S-4 to register exchange offers for $5,204,174,000 aggregate principal amount of senior notes. Holders may exchange their outstanding initial notes for new exchange notes with substantially identical terms, except the exchange notes are registered and do not carry Holcim Ltd guarantees.
The series include 3.500% due 2026, 4.600% due 2027, 4.700% due 2028, 4.950% due 2030, 4.200% due 2033, 5.400% due 2035, 7.125% due 2036, 6.875% due 2039, 6.500% due 2043 and 4.750% due 2046. The notes are senior unsecured obligations of the issuer and are guaranteed on a senior unsecured basis by Amrize Ltd. The filing states the exchange offers are made to satisfy registration rights agreements and will not generate cash proceeds.
Amrize became an independent public company following Holcim’s spin-off on June 23, 2025. Exchanging initial notes for exchange notes is not a taxable event for U.S. federal income tax purposes. Broker-dealers receiving exchange notes for market-making activities must deliver a prospectus when reselling.
The Vanguard Group filed a Schedule 13G reporting a passive stake in Amrize Ltd. Vanguard disclosed beneficial ownership of 30,094,083 shares of common stock, representing 5.3% of the class as of 09/30/2025. The filing lists 0 shares with sole voting power and 7,449,100 with shared voting power, along with 20,520,828 shares under sole dispositive power and 9,573,255 under shared dispositive power.
Vanguard certified the securities were acquired and are held in the ordinary course of business and not to change or influence control. The firm is identified as an investment adviser. Vanguard’s clients, including registered investment companies and other managed accounts, may receive dividends or sale proceeds tied to these securities, and no single other person’s interest exceeds 5%.
Amrize Ltd (AMRZ) reported Q3 2025 results. Revenue rose to $3,675 million from $3,446 million, while diluted EPS was $0.98 versus $1.00 a year ago. Gross profit improved to $1,086 million, but operating income declined to $778 million as selling, general and administrative expenses increased to $312 million.
By segment, Building Materials revenue was $2,774 million with Segment Adjusted EBITDA of $902 million, and Building Envelope revenue was $901 million with Segment Adjusted EBITDA of $217 million. For the first nine months, revenue was $8,976 million and diluted EPS was $1.60.
Following its June 2025 spin-off from Holcim, Amrize reshaped its capital structure: long-term debt was $4,932 million, including new senior notes issued earlier in 2025 and exchanged notes, and commercial paper outstanding of $547 million. Cash and cash equivalents were $826 million. Operating cash flow for the nine months was $404 million, with capital expenditures of $631 million. Shares outstanding were 553,082,069 as of September 30, 2025.
Amrize Ltd furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025, and an investor presentation. The materials are furnished under Items 2.02 and 7.01 and made available as Exhibits 99.1 and 99.2, dated October 28, 2025.
The company notes these materials are furnished, not filed, under the Exchange Act and are available on its investor website.
BlackRock, Inc. filed Amendment No. 1 to Schedule 13G reporting a passive stake in Amrize Ltd common stock. As of 09/30/2025, BlackRock beneficially owned 38,010,769 shares, representing 6.9% of the class.
The filing lists sole voting power over 35,939,276 shares and sole dispositive power over 38,010,769 shares, with no shared voting or dispositive power. BlackRock certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Amrize Ltd (AMRZ) insider purchase: On 08/27/2025 Amrize CTO Roald Brouwer acquired 2,000 ordinary shares at $51.88 per share, increasing his beneficial holdings to 5,000 shares. The Form 4 shows the purchase was executed in Swiss francs at CHF 41.835 per share and converted to U.S. dollars using the transaction date exchange rate (USD 1.00 = CHF 0.8064). The filing was signed by Hans Weinburger as attorney-in-fact. The report indicates this was a direct purchase and the filer remains an officer of the company.